189 related articles for article (PubMed ID: 34087223)
1. Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy.
Xiao MC; Qian H; Huang CK; Zheng BN; Yan FZ; Liu F; Zhang X; Chen SJ; Luo C; Xie WF
Eur J Pharmacol; 2021 Sep; 906():174217. PubMed ID: 34087223
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
3. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
4. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
5. The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Wang J; Wei H; Huang Y; Chen D; Zeng G; Lian Y; Huang Y
Aging (Albany NY); 2019 Aug; 11(15):5769-5785. PubMed ID: 31409760
[TBL] [Abstract][Full Text] [Related]
6. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3‑kinase/protein kinase B pathway.
Zhang B; Yin X; Sui S
Oncol Rep; 2018 Nov; 40(5):2758-2765. PubMed ID: 30132535
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
Deng M; Li L; Zhao J; Yuan S; Li W
Cancer Chemother Pharmacol; 2018 May; 81(5):853-862. PubMed ID: 29532153
[TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.
Chen L; Ye HL; Zhang G; Yao WM; Chen XZ; Zhang FC; Liang G
PLoS One; 2014; 9(1):e85771. PubMed ID: 24465696
[TBL] [Abstract][Full Text] [Related]
11. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
12. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
13. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
[No Abstract] [Full Text] [Related]
14. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
Zhao F; Feng G; Zhu J; Su Z; Guo R; Liu J; Zhang H; Zhai Y
Anticancer Drugs; 2021 Apr; 32(4):386-393. PubMed ID: 33395067
[TBL] [Abstract][Full Text] [Related]
15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
16. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.
Li L; Yu S; Hu Q; Hai Y; Li Y
Int J Biol Sci; 2021; 17(12):3133-3144. PubMed ID: 34421355
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
18. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
Ma D; Wang J; Liu L; Chen M; Wang Z
BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
[TBL] [Abstract][Full Text] [Related]
19. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.
Yin F; Feng F; Wang L; Wang X; Li Z; Cao Y
Cell Death Dis; 2019 Sep; 10(9):672. PubMed ID: 31511501
[TBL] [Abstract][Full Text] [Related]
20. Liposomal clodronate combined with Cisplatin or Sorafenib inhibits hepatocellular carcinoma cell proliferation, migration and invasion by suppressing FOXQ1 expression.
Zhou Y; Chen Y; Ma C; Shao B; Zhang F
Cell Mol Biol (Noisy-le-grand); 2020 Apr; 66(1):49-54. PubMed ID: 32359383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]